Scalper1 News
Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched coverage at outperform with a price target of 35. His move came a day after Arrowhead received FDA permission to launch a phase 2a trial of hepatitis B drug ARC-520, which Yee believes could eventually Scalper1 News
Scalper1 News